Objective: This systematic review and meta-analysis aims to evaluate the diagnostic accuracy of various point-of-care devices for detecting deficiency of glucose-6-phosphate dehydrogenase among malaria patients.
Methods: A comprehensive literature search was performed. Data extracted include the number of true positives, false negatives, false positives and true negatives to calculate sensitivity and specificity for various devices. CareStart G6PD rapid diagnostic test and the STANDARD G6PD Biosensor were assessed against spectrophotometry (gold standard) at clinically relevant activity thresholds of 30% and 70%. Pooled estimates were generated using a random-effects model in R (version 4.3.1). Risk of bias was assessed using the QUADAS-2 tool. The protocol was registered in the International Prospective Register of Systematic Reviews (PROSPERO) database with reference ID CRD420251122222.
Results: A total of 13 cross-sectional studies were included. At the 30% threshold the pooled sensitivity of CareStart was 0.82 (95% CI: 0.55-0.95) and specificity was 0.96 (95% CI: 0.93-0.98). At a 70% threshold the pooled sensitivity of CareStart was 0.54 (95% CI: 0.31-0.76), although specificity remained high at 0.96 (95% CI: 0.84-0.99). For the STANDARD G6PD Biosensor, the pooled sensitivity at 30% and 70% was 0.99 (95% CI: 0.96-1.00) and 0.96 (95% CI: 0.90-0.98), respectively, while the pooled specificity values for the above thresholds were 0.98 (95% CI: 0.97-0.99) and 0.96 (95% CI: 0.89-0.99).
Conclusion: Quantitative point-of-care testing using STANDARD G6PD Biosensor demonstrates superior diagnostic performance, particularly for identifying intermediate G6PD activity, supporting its preferential use for guiding safe radical cure with 8-aminoquinoline therapies in malaria-endemic settings.
Keywords: G6PD deficiency; glucose‐6‐phosphate dehydrogenase deficiency; malaria; point‐of‐care devices.
© 2026 John Wiley & Sons Ltd.